| Primary |
| Product Used For Unknown Indication |
64.7% |
| Hypertension |
17.6% |
| Hepatitis C |
5.9% |
| Pulmonary Sepsis |
5.9% |
| Tooth Abscess |
5.9% |
|
| Renal Failure Acute |
30.0% |
| Hyponatraemia |
10.0% |
| Interstitial Lung Disease |
10.0% |
| Speech Disorder |
10.0% |
| Thrombocytopenia |
10.0% |
| Thrombosis |
10.0% |
| Ventricular Tachycardia |
10.0% |
| Weight Increased |
10.0% |
|
| Secondary |
| Drug Use For Unknown Indication |
29.0% |
| Laryngeal Neoplasm |
12.5% |
| Hypertension |
12.0% |
| Pharyngeal Neoplasm |
12.0% |
| Cardiac Failure |
7.5% |
| Myocardial Ischaemia |
3.0% |
| Pain |
2.5% |
| Benign Prostatic Hyperplasia |
2.0% |
| Cardiac Failure Congestive |
2.0% |
| Lung Disorder |
2.0% |
| Respiratory Disorder |
2.0% |
| Urinary Tract Infection |
2.0% |
| Atrial Fibrillation |
1.5% |
| Cardiac Failure Chronic |
1.5% |
| Coronary Artery Disease |
1.5% |
| Essential Hypertension |
1.5% |
| Hiv Infection |
1.5% |
| Hot Flush |
1.5% |
| Renal Transplant |
1.5% |
| Arthralgia |
1.0% |
|
| Renal Failure Acute |
13.3% |
| Muscle Hypertrophy |
8.9% |
| Angioneurotic Oedema |
6.7% |
| Hepatitis Cholestatic |
6.7% |
| Rash |
6.7% |
| Renal Failure |
6.7% |
| Rhabdomyolysis |
6.7% |
| Atrial Fibrillation |
4.4% |
| Hepatic Enzyme Increased |
4.4% |
| Hyponatraemia |
4.4% |
| Jaundice |
4.4% |
| Rash Papulosquamous |
4.4% |
| Thrombocytopenia |
4.4% |
| Vision Blurred |
4.4% |
| Drug Interaction |
2.2% |
| Hepatitis |
2.2% |
| Hypoglycaemia |
2.2% |
| Indifference |
2.2% |
| Infarction |
2.2% |
| Lipase Increased |
2.2% |
|
| Concomitant |
| Drug Use For Unknown Indication |
30.2% |
| Hypertension |
28.1% |
| Diabetes Mellitus |
5.0% |
| Pain |
3.7% |
| Rheumatoid Arthritis |
3.5% |
| Essential Hypertension |
3.0% |
| Atrial Fibrillation |
2.7% |
| Product Used For Unknown Indication |
2.7% |
| Osteoporosis |
2.4% |
| Prophylaxis |
2.2% |
| Hypercholesterolaemia |
2.0% |
| Dyspepsia |
1.8% |
| Type 2 Diabetes Mellitus |
1.8% |
| Urinary Tract Infection |
1.7% |
| Breast Cancer |
1.6% |
| Cardiac Failure |
1.6% |
| Ischaemic Heart Disease Prophylaxis |
1.6% |
| Metastatic Gastric Cancer |
1.6% |
| Atypical Mycobacterial Infection |
1.5% |
| Chronic Obstructive Pulmonary Disease |
1.5% |
|
| Vomiting |
11.4% |
| Renal Failure Acute |
9.1% |
| Tremor |
8.3% |
| Thrombocytopenia |
6.8% |
| Rhabdomyolysis |
6.1% |
| Weight Increased |
6.1% |
| Vision Blurred |
5.3% |
| Myocardial Infarction |
4.5% |
| Pyrexia |
4.5% |
| International Normalised Ratio Increased |
3.8% |
| Rash |
3.8% |
| Somnolence |
3.8% |
| Staphylococcal Infection |
3.8% |
| Syncope |
3.8% |
| Transaminases Increased |
3.8% |
| Bronchospasm |
3.0% |
| Hyperkalaemia |
3.0% |
| Malaise |
3.0% |
| Renal Failure |
3.0% |
| Respiratory Distress |
3.0% |
|
| Interacting |
| Hypertension |
16.1% |
| Product Used For Unknown Indication |
12.9% |
| Cardiac Failure Congestive |
9.7% |
| Essential Hypertension |
9.7% |
| Myocardial Ischaemia |
9.7% |
| Drug Use For Unknown Indication |
6.5% |
| Otitis Media Chronic |
6.5% |
| Sinusitis |
6.5% |
| Atrial Fibrillation |
3.2% |
| Cardiac Disorder |
3.2% |
| Depression |
3.2% |
| Dyslipidaemia |
3.2% |
| Polycythaemia |
3.2% |
| Prophylaxis Against Gastrointestinal Ulcer |
3.2% |
| Type 2 Diabetes Mellitus |
3.2% |
|
| Renal Failure Acute |
85.7% |
| Renal Failure Chronic |
14.3% |
|
